Key points are not available for this paper at this time.
Continuing five or more locoregional therapies for recurrent HCC after LR is related to poor recurrence-free survival after SLT.
Share your take
Add a clinician perspective alongside expert commentary.
Rhu et al. (2018) studied this question.